Navigation Links
New USP 797 Regulations May Create New Hazards for Compounding Pharmacy Directors
Date:9/23/2008

AGAWAM, Mass., Sept. 23 /PRNewswire/ -- Though the new USP 797 regulations, which become effective June 1st, ease testing requirements, the impact of following the new minimums has the potential of creating new hazards for compounding pharmacy directors, warns Steven Wieczorek, Supervisor, Environmental Sciences, Microtest, Inc.

Issued by the U.S. Pharmacopoeia, the new version of USP 797 establishes bi-annual environmental sampling and testing as a minimum requirement, in place of the former monthly frequency. The regulations continue to require that pharmacies preparing compounded sterile preparations must have an effective plan and program that incorporate best practices and provide a clean, sterile working environment free of contamination.

Potential Hazards from Hidden Impacts

But Wieczorek says that adopting a bi-annual environmental testing program may impact a facility's capability to maintain compliance. "Compounding pharmacy directors need to recognize the series of potential hazards lurking for them within the 'hidden impacts' of the new regulations." Those hazards, he said, include:

-- Bi-annual testing will not capture seasonal blooms of yeast, fungi, and bacteria.

-- Problem tracking, diagnosis, and resolution will be difficult if environmental testing is conducted at six month intervals.

-- The development of trend data that shows important seasonal fluctuations will be impossible when conducting bi-annual environmental testing.

-- If a failure occurs during a bi-annual testing program, investigating up to 6 months of compounding activities and justifying what may or may not have been affected will be nearly impossible and extremely time consuming.

-- With a monthly testing program, a failure will require investigation of only 3 to 4 weeks of data and will be significantly easier -- saving large amounts of time and money. It will also help insure that the compounds prepared in your facility are sterile and will provide a safer final product for patients.

-- Testing at a higher frequency will provide peace of mind. You will know that your controlled compounding environment(s), policies, and technicians are under control and in compliance. This will help reduce infections and save lives.

Wieczorek and Microtest (Agawam, Mass., http://www.microtestlabs.com/usp797) will continue to recommend a monthly testing regimen for all pharmacies compounding sterile preparations.

"A monthly testing regimen will continue to provide critical environmental and trend data of a pharmacy as the seasons change. Monthly testing will better reflect continued control of the compounding environment. It also will enable rapid problem resolution at a time when facilities are most vulnerable to non-compliance issues," Wieczorek said.

"Under the regulations, the pharmacy director holds quality control responsibility and is accountable for the facility's compliance performance. We believe that embracing best practices to create a plan that meets the pharmacy's specific environment will achieve the greatest success," he said.

Pharmacies failing to comply with USP 797 risk exposure to patient lawsuits as well as the potential loss of The Joint Commission's (JCAHO) accreditation.

Free Facility-Gap-Analysis Audit

To help pharmacy directors set a benchmark, Microtest offers a free facility-gap-analysis audit to help compounding pharmacies determine their USP 797 compliance level and corresponding preparation. The audit includes an examination of the compounding pharmacy service's physical facility footprint, drug compounding procedures, operational policies and training programs. Microtest experts will determine the level of compliance achieved, existing level of risk exposure, and recommendations to achieve compliance to USP 797.

"The audit will recommend the designated sterile compounding risk level of the pharmacy service as well as establish an accurate baseline for compliance program next-action development," Wieczorek said "With the audit in-hand, pharmacy directors can then create a service plan."

Microtest offers compounding pharmacy directors a single, one-stop resource of complete USP 797 compliance solutions -- as advice, assistance, or complete implementation -- available in an incremental approach or as a comprehensive, turnkey solution. Services include: program implementation, onsite training, custom SOP documentation, clean room design, environmental monitoring, and CSP product testing. To learn more, on the Web, visit http://www.microtestlabs.com/usp797 or call toll-free 1-800-631-1680.

About Microtest

Microtest is a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries. Based in Agawam, Massachusetts, USA, the company's expertise and flexible processes enhance product safety and security, accelerate time to market, and minimize supply chain disruption. For more information, visit http://www.microtestlabs.com or call 1-413-786-1680 or toll-free 1-800-631-1680.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Steve Richter, Ph.D. https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=42622


'/>"/>
SOURCE Microtest Labs
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Autonomy Meridio Enables Extract Technology to Enhance Capabilities in Compliance With Manufacturing Regulations
2. Free White Paper Addresses Challenges of New FDA Regulations Awaiting Combo Product Manufacturers
3. CU scientists create worlds thinnest balloon -- just one atom thick
4. NPL to create encyclopedia for space nanomaterials
5. Using nanotechnology to create high-performance materials
6. New process creates 3-D nanostructures with magnetic materials
7. PacificGMP to Merge With Pacific Biopharma Group and Create Innovative US-Compliant cGMP Contract Biomanufacturing Facility in China
8. China Sun Group High-Tech Co. Completes Share Exchange to Create 100% Ownership in DLX Subsidiary
9. Monsantos Industry-Leading Seed Position Creates Accelerated Biotech Trait Opportunity in Latin America
10. Inclinix Expansion Creates New Position and Promotions
11. Weizmann Institute scientists create new nanotube structures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 2017 , ... A study recently published in Spine shows ... center (ASC) with satisfactory clinical and patient-reported outcomes, when compared to anterior cervical ... Lubinski, president of AxioMed, commented on the recent publication, stating, “We see cervical ...
(Date:2/24/2017)... Calif. (PRWEB) , ... February 24, 2017 , ... Chef ... and wine scene. Making stops in several cities, she gained a number of ... adventure began in Stellenbosch, a town in South Africa’s Western Cape province. It ...
(Date:2/24/2017)... 24, 2017  Aethlon Medical, Inc. (Nasdaq: ... its Chairman and CEO, Jim Joyce . ... Conference last Saturday, Bill Gates warned world ... people than nuclear weapons. Mr. Gates expressed his concern, ... agencies, that scientific terrorists have access to the necessary ...
(Date:2/24/2017)... 2017  Driven by consumers, preference towards more ... fastest growing categories, finds the recently published U.S. ... Care: Multi-regional Market Analysis and Opportunities study ... Kline. "Biotechnology actives are derived from ... effective for skin and hair care applications," explains ...
Breaking Biology Technology:
(Date:2/2/2017)... 2, 2017   TapImmune, Inc. (NASDAQ: ... specializing in the development of innovative peptide and ... cancer and metastatic disease, announced today it has ... of a second clinical lot of TPIV 200, ... alpha. The manufactured vaccine product will be used ...
(Date:2/2/2017)... , Feb. 1, 2017  Central to ... and meaningful advances worldwide, The Japan Prize Foundation ... Prize, who have pushed the envelope in their ... and Communication. Three scientists are being recognized with ... achievements that not only contribute to the advancement ...
(Date:1/31/2017)... Mass. , Jan. 31, 2017  Spero ... novel therapies for the treatment of bacterial infections, ... set of antibacterial candidates from Pro Bono Bio ... increased prevalence of multi-drug resistant forms of Gram-negative ... Cantab Anti Infectives Ltd, a PBB group company. ...
Breaking Biology News(10 mins):